- Memorandum of Understanding (MoU) with leading Indonesian biomedical company PT Etana Biotechnologies
- MoU aims to facilitate late-stage clinical trials in
Indonesia , supporting the Indonesian Government’s access to novel infectious disease medicines - Opportunity to access 10
ASEAN member states1 covering a population of 670 million inhabitants - Patient populations readily available focused on significant unmet medical needs particular to the region
- Significant bilateral initiative supported by the Australian and Indonesian governments
“The global health challenge of antimicrobial resistance is a pressing issue on the world stage,” said
This is a historically significant bilateral initiative supported by the Australian and Indonesian governments. In a meeting together with Senior Executives from Recce and Etana, Her Excellency Penny Williams PSM, the Australian Ambassador to
Recce will collaborate with nationally selected biotech sponsor Etana to advance its clinical program with speed, accessibility, cost-effectiveness, including substantial government support, and quality. Coordinating bilateral efforts between the Australian and Indonesian governments and industry experts will provide Recce with market entry and penetration for international expansion opportunities.
There is a significant need for new therapeutics in
About Etana
Established in 2014, Etana is an Indonesian biopharmaceutical company that researches, manufactures and markets biological therapies for the Southeast Asian market. With a mission to serve patients by providing high quality, affordable, and innovative therapies, Etana has built state-of-the-art local production facility that meet international and Indonesian FDA standards. The facility is able to produce biological therapy with halal certification from the
About
Recce’s anti-infective pipeline includes three patented, broad-spectrum, synthetic polymer anti-infectives: RECCE® 327 as an intravenous and topical therapy that is being developed for the treatment of serious and potentially life-threatening infections due to Gram-positive and Gram-negative bacteria including their superbug forms; RECCE® 435 as an orally administered therapy for bacterial infections; and RECCE® 529 for viral infections. Through their multi-layered mechanisms of action, Recce’s anti-infectives have the potential to overcome the hypercellular mutation of bacteria and viruses – the challenge of all existing antibiotics to date.
The FDA has awarded RECCE® 327 Qualified Infectious Disease Product designation under the Generating Antibiotic Initiatives Now (GAIN) Act – labelling it for Fast Track Designation, plus 10 years of market exclusivity post approval. Further to this designation, RECCE® 327 has been included on The Pew Charitable Trusts Global New Antibiotics in Development Pipeline as the world’s only synthetic polymer and sepsis drug candidate in development. RECCE® 327 is not yet market approved for use in humans with further clinical testing required to fully evaluate safety and efficacy.
Recce wholly owns its automated manufacturing, which is supporting present clinical trials. Recce’s anti-infective pipeline seeks to exploit the unique capabilities of its technologies targeting synergistic, unmet medical needs.
Corporate Contact
+61 (02) 9256 2571
James.graham@recce.com.au
Media & Investor Relations (AU)
CityPR
+61 (02) 9267 4511
ageddes@citypublicrelations.com.au
Media (
mfitzhugh@lifescicomms.com
Investor Relations (
gvanrenterghem@lifesciadvisors.com
1 https://asean.org/member-states/
2 https://idf.org/our-network/regions-and-members/western-pacific/members/indonesia/
3 https://www.verywellhealth.com/what-are-the-common-infections-with-diabetes-1087622
4 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5332551/
Source:
2024 GlobeNewswire, Inc., source